Mineralocorticoid receptor antagonists (MRAs) have demonstrated safe and effective clinical use over decades to treat hypertension and heart failure in patients with cardiovascular disease, primarily through reductions in blood pressure, cardiac load, and fibrosis (Ferrario and Schiffrin, 2015). Here, NR3C2 is linked to heart failure.